Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Tetra Bio-Pharma Provides Update on its Neuropathic and Chronic Pain Drug Development Program | ||
By: Nasdaq / GlobeNewswire - 12 Feb 2019 | Back to overview list |
|
ORLEANS, Ontario, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-derived drug development and discovery, today announced accelerated development of its second-generation drug inhalation program for fibromyalgia and uncontrolled pain over the last months. A Phase 1 study in healthy volunteers using vaporized PPP001 was successfully completed (click here) and the Corporation filed a patent application after unexpectedly discovering the unique composition of cannabis smoke. In July 2018, the Corporation entered into a co-development agreement with Storz & Bickel, widely recognized as the global leader in vaporizer design and manufacturing. Tetra incorporated the vaporizer into its smoke-vapor research program as it aimed to understand how inhaled cannabis relieves pain for patients. About Neuropathic Pain (Fibromyalgia) and Chronic Pain Tetra gained knowledge and understanding as to how smoked and vaporized cannabis works to relieve pain, based on its double-blind randomized placebo-controlled studies of PPP001 administered with the titanium pipe and Mighty Medic vaporizer and the use of smoke-vapor trapping studies to quantify exposure to the respiratory tract. A significant finding of the study was learning how much of each cannabinoid and terpene is delivered to the human body as the result of smoking or vaporizing a dried cannabis product. The key to the success of a smoked cannabis product is closely linked to its speed of delivery to the brain. In addition, the inhalation mode of delivery results in significantly higher maximal plasma levels at the peak of treatment. What does this mean? Essentially, results from our study in humans showed that the peak therapeutic levels show only a 1-minute difference in delivery between the pipe and vaporizer. Combined with the speed, the levels of cannabinoids delivered at this peak of exposure are what results in the benefits seen in patients who suffer from pain. The pipe or vaporizer delivered important differences in some cannabinoids and terpenes. Tetra is using this insight to accelerate the development of alternative formulations for the treatment of fibromyalgia and uncontrolled chronic pain. This knowledge is incorporated in the filed patent application and based on this, Tetra will use isolates or synthetic-based supplies of cannabinoids and terpenes to develop these prescription cannabinoid-derived medicines. During the last quarter of 2018, the Corporation began preparations for a research site in the United States to conduct its fibromyalgia clinical trial and we are intent on expanding clinical sites in Canada and in the USA in 2019. "We previously communicated that after reviewing the human clinical data, Tetra anticipated proceeding into phase 2 clinical trials in fibromyalgia patients,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “We are committed to this target and plan to accelerate this development in the USA as well. Tetra has and continues to gain tremendous credibility within the medical community. We earned this credibility because of our clinical studies and exhaustive characterization of the pharmaceutical composition of cannabis-derived smoke and vaporization products. Overall, 2018 was a productive year after completing several clinical trials and we expect 2019 to build on this as we accelerate this program." About Tetra Bio-Pharma For more information visit: www.tetrabiopharma.com Source: Tetra Bio-Pharma Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-looking statements For further information, please contact Tetra Bio-Pharma Inc. Media Contact: Marissa Zanti i Https:// https://www.cdc.gov/arthritis/basics/fibromyalgia.htm ii MEDTRACK |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |